Big data are used in the pursuit of precision medicine in the general population. Applying these tools to patients with sickle cell disease (SCD) is essential for ensuring that they receive the most appropriate customized therapy for their disease. For these tools to be applied, there must be a large number of willing, fully phenotyped participants…

Sickle cell disease (SCD) is an inherited blood condition resulting from abnormal hemoglobin production. It is one of the most common genetic diseases in the world. The clinical manifestations are variable and range from recurrent acute and debilitating painful crises to life-threatening pulmonary, cardiovascular, renal, and neurologic complication…

The prospect of a clinical strategy using an adeno-associated virus (AAV) vector for expression of therapeutic levels of factor VIII (FVIII) has been highly desirable. This was initially anticipated by promising data from clinical studies on AAV5-FVIII in men with severe hemophilia A. However, long-term follow-up showed a unique efficacy concern on…

The availability of novel nonfactor therapeutics is revolutionizing the management of hemophilia in individuals with inhibitory antibodies, as well as making prophylaxis more convenient even in the absence of inhibitors. Unfortunately, the use of these products has been associated with thrombotic events that are not typically seen with factor repla…

Amy Shapiro discusses the recent approval of concizumab for the treatment of patients with hemophilia. This novel subcutaneous homeostatic rebalancing agent has proven to be useful for the treatment of patients with hemophilia A and B, and we hope you find this talk to be useful to understand it.Από τον Blood Advances Talks

Allogeneic hematopoietic stem cell transplantation (HCT) is curative in many patients with advanced hematopoietic malignancies. Donor T cells not only facilitate engraftment and protect against opportunistic pathogens and residual disease, but can also cause graft-versus-host disease (GVHD), with significant morbidity and mortality.…

The high incidence of thromboembolic disease, and in particular venous thromboembolism (VTE), has emerged as an important consideration in hospitalized and critically ill patients with coronavirus disease 2019 (COVID-19).Από τον Blood Advances Talks

The treatment of hemophilia, which has undergone many transformative changes over the past 60 years, is poised for yet another disruptive change: the use of gene therapy to produce functional cures in some persons with hemophilia A or B.Από τον Blood Advances Talks

The changing landscape of anticoagulation in cancer-associated thrombosisΑπό τον Blood Advances Talks

Από τον Blood Advances Talks

Inherited predisposition to myeloid malignancies by Blood Advances TalksΑπό τον Blood Advances Talks

Managing patients who are receiving warfarin (or DOAC)and need an elective surgery or procedure by Blood Advances TalksΑπό τον Blood Advances Talks

Daily light-and-darkness onset regulates mouse hematopoietic stem cells by Blood Advances TalksΑπό τον Blood Advances Talks

Extended therapy for unprovoked venous thromboembolism: when is it indicated? by Blood Advances TalksΑπό τον Blood Advances Talks

Antiplatelet therapy in the management of atherothrombosis: recent clinical advances by Blood Advances TalksΑπό τον Blood Advances Talks

Challenges facing the benign hematology physician-scientist workforce by Blood Advances TalksΑπό τον Blood Advances Talks

Choosing for whom to recommend allogeneic transplantation for AML in CRL by Blood Advances TalksΑπό τον Blood Advances Talks

Catalyzing innovation in clinical trial design and analysis at NHLBI by Blood Advances TalksΑπό τον Blood Advances Talks

ITP and thrombosis: an intriguing association by Blood Advances TalksΑπό τον Blood Advances Talks

The current therapeutic landscape of FLT3 inhibitors by Blood Advances TalksΑπό τον Blood Advances Talks

How many mice? Design considerations for murine studies by Blood Advances TalksΑπό τον Blood Advances Talks

The Direct Oral Anticoagulants – can we finally stop using rat poison? by Blood Advances TalksΑπό τον Blood Advances Talks

Impact of the ICAL on the treatment of acute leukemia by Blood Advances TalksΑπό τον Blood Advances Talks

Venetoclax: a primer by Blood Advances TalksΑπό τον Blood Advances Talks

Technological Solutions For Global Hematology And Oncology by Blood Advances TalksΑπό τον Blood Advances Talks

The Lucky Iron Fish: a simple solution for iron deficiency by Blood Advances TalksΑπό τον Blood Advances Talks

New developments in the management of sickle cell disease by Blood Advances TalksΑπό τον Blood Advances Talks

Should we avoid heparin to eliminate HIT? by Blood Advances TalksΑπό τον Blood Advances Talks